4
Changes in Ownership
CORCEPT THERAPEUTICS INC Filed Acc 0001193125-26-330668
Chief Financial Officer sold 80,000 shares at an average $114.71 ($9,177,109)
- Chief Financial Officer acquired 80,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Mokari Atabak · Chief Financial Officer
Table I: Non-derivative
14 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-07-30 | Exercise or conversion : show line 1 in the form 10b5-1 | +80,000 | $23.06 | $1,844,800 | 96,130 | D |
| 2026-07-30 | Sale : show line 2 in the form 10b5-1 | −4,200 | $105.54 | $443,248 | 91,930 | D |
| 2026-07-30 | Sale : show line 3 in the form 10b5-1 | −8,956 | $106.96 | $957,892 | 82,974 | D |
| 2026-07-30 | Sale : show line 4 in the form 10b5-1 | −400 | $108.46 | $43,384 | 82,574 | D |
| 2026-07-30 | Sale : show line 5 in the form 10b5-1 | −2,202 | $110.03 | $242,282 | 80,372 | D |
| 2026-07-30 | Sale : show line 6 in the form 10b5-1 | −600 | $110.95 | $66,570 | 79,772 | D |
| 2026-07-30 | Sale : show line 7 in the form 10b5-1 | −4,700 | $113.18 | $531,941 | 75,072 | D |
| 2026-07-30 | Sale : show line 8 in the form 10b5-1 | −15,477 | $114.96 | $1,779,237 | 59,595 | D |
| Open-market sales · 80,000 sh · avg $114.71 · $9,177,109 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-07-30 | Exercise or conversion : show line 15 in the form 10b5-1 Stock option (right to buy) | −80,000 | 95,833 | D |
Loading xslF345X06/ownership.xml…